Dynavax Announces Termination Of Partnership With Merck For HEPLISAV™ Hepatitis B Vaccine – All Rights Revert To Dynavax
Wednesday, December 31st, 2008Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the termination of a global license and development collaboration agreement with Merck & Co., Inc. for HEPLISAVTM, a Phase 3 hepatitis B virus (HBV) vaccine. All rights to develop and commercialize HEPLISAV revert to Dynavax.
Lees meer..